We are live on ! Find out more
CRMD icon

CorMedix

79 hedge funds and large institutions have $107M invested in CorMedix in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $4.2M | Put options by funds: $2.14M

57% more capital invested

Capital invested by funds: $68.7M → $107M (+$38.8M)

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

5% more funds holding

Funds holding: 7579 (+4)

4.74% more ownership

Funds ownership: 28.83%33.56% (+4.7%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
79
Holders Change
+4
Holders Change %
+5.33%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
26
Reduced
21
Closed
12
Calls
$4.2M
Puts
$2.14M
Net Calls
+$2.06M
Net Calls Change
+$2.48M

CRMD Hedge Fund Activity: Q1 2021 in Review

79 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2021, worth a combined $107M — up 57% from $68.7M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new CRMD positions and 12 closed out — a net gain of 4 holders — while 26 added to existing stakes and 21 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $7.93M. The largest seller was Elliott Investment Management, cutting an estimated $2.19M.

  • 79 institutional investors held CorMedix (CRMD) as of Q1 2021, up from 75 in Q4 2020.
  • Funds reported $107M of CorMedix stock for Q1 2021, up 57% quarter-over-quarter.
  • 16 funds opened new CorMedix positions in Q1 2021 and 12 closed out, a net change of +4 holders.
  • The largest CorMedix buyer in Q1 2021 was Credit Suisse, an estimated $7.93M added.
  • The largest CorMedix seller in Q1 2021 was Elliott Investment Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q1 2021.